Antimitotic drugs in the treatment of cancer Rustelle Janse van VuurenMichelle H. VisagieAnnie M. Joubert Review Article Open access 12 November 2015 Pages: 1101 - 1112
Targeted therapy in cancer Apostolia-Maria Tsimberidou Review Article 21 September 2015 Pages: 1113 - 1132
The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment F. JinM. RobesonS. Ramanathan Original Article 02 November 2015 Pages: 1133 - 1141
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors Yutaka FujiwaraHiroshi NokiharaTomohide Tamura Original Article 03 November 2015 Pages: 1143 - 1152
A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors Shinji NakamichiHiroshi NokiharaTomohide Tamura Original Article Open access 03 November 2015 Pages: 1153 - 1161
Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients Ping LiuYing WangHong Ni Original Article 05 November 2015 Pages: 1163 - 1171
Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression Xianbing PengQun ZhangPing Ai Original Article 06 November 2015 Pages: 1173 - 1184
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients Jose FrancisBiswajit DubashiAdithan Chandrasekaran Original Article 06 November 2015 Pages: 1185 - 1189
Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer Shogo KobayashiAkira TomokuniMasato Sakon Original Article 07 November 2015 Pages: 1191 - 1198
Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts Nikki P. LeeKin Tak ChanSimon Law Original Article 09 November 2015 Pages: 1199 - 1207
Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO) Taishi HataMichitaka HondaHideyuki Mishima Original Article 11 November 2015 Pages: 1209 - 1215
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer Tatsuya KuriharaMari KogoYuji Kiuchi Original Article 11 November 2015 Pages: 1217 - 1224
Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer Haruko DagaKoji TakedaKazuhiko Nakagawa Original Article 11 November 2015 Pages: 1225 - 1233
Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation Oukseub LeeDavid IvancicSeema A. Khan Original Article 11 November 2015 Pages: 1235 - 1246
Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells Lijun WangYing WangHong Xiao Original Article 13 October 2015 Pages: 1247 - 1257
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma Matthew D. GalskyNoah M. HahnWilliam K. Oh Original Article 13 October 2015 Pages: 1259 - 1265
Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study Young Saing KimSun Jin SymDong Bok Shin Original Article 19 October 2015 Pages: 1267 - 1272
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors Elizabeth FoxBrigitte C. WidemannFrank M. Balis Original Article 20 October 2015 Pages: 1273 - 1283
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction Maarten J. DeenenDidier MeulendijksAnnemieke Cats Original Article 23 October 2015 Pages: 1285 - 1295
Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy Joy Marie FulbrightDaniela E. Egas-BejarJoya Chandra Original Article 29 October 2015 Pages: 1297 - 1307
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer Zheng WuAndrew GabrielsonAiwu Ruth He Clinical Trial Report 27 October 2015 Pages: 1309 - 1314
Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives Nuggehally R. Srinivas Letter to the Editor 11 November 2015 Pages: 1315 - 1316
Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug–drug interaction Marta KoršićDavorka MuršićBranka Čučević Letter to the Editor 20 October 2015 Pages: 1317 - 1319